secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001193125-24-283212
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs
--------------------------------------------------------------------------------

- Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.
- Warrants exercisable at $1.19/share for 5.5 years, beginning 6 months after issuance.
- Proceeds to fund BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26).
- Proceeds also to fund mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26).
- Officers and directors subject to 75-day lock-up; company restricted on equity issuance for 75 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/0001193125-24-283212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/d823541d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-283212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer